Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.38 |
| ▸ | TXNRD3 | Q86VQ6 | 2/20 | 0.38 |
| ▸ | TXNRD2 | Q9NNW7 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196884 | 1.00 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL13196871 | 0.88 | MEN1 (0.43) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL2790622 | 0.88 | MEN1 (0.43) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL2787391 | 0.84 | PIK3CD (0.46) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL2787394 | 0.84 | PIK3CD (0.46) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL13196946 | 0.83 | KMT2A (0.38) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL13196869 | 0.75 | MEN1 (0.36) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL2789845 | 0.75 | MEN1 (0.36) | MEN1KMT2AMAPTALDH1A1PKM | |
| SCHEMBL2788626 | 0.75 | CISD1 (0.40) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL13196880 | 0.75 | CISD1 (0.40) | MEN1KMT2AMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | claimed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | claimed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | claimed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | claimed |
| EP-1567112-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1567112-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004047760-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | claimed |
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | disclosed |
| EP-1567112-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1567112-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047760-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293338-A1 | Novel chemical compounds | HIPK3, HIPK1, HIPK4 | MEN1 4161/4885KMT2A 3255/4885MAPT 1782/4885 |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | MEN1 2870/4885KMT2A 3096/4885MAPT 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.